Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Haig Inguilizian"'
Autor:
Richard Kim, Alexis D. Leal, Aparna Parikh, David P. Ryan, Shining Wang, Brittany Bahamon, Neeraj Gupta, Aaron Moss, Joanna Pye, Harry Miao, Haig Inguilizian, James M. Cleary
Publikováno v:
Cancer Chemotherapy and Pharmacology. 91:291-300
Purpose Guanylyl cyclase C (GCC) is highly expressed in several gastrointestinal malignancies and preclinical studies suggest that it is a promising target for antibody-based therapeutics. This phase I trial assessed the safety and tolerability of TA
Autor:
Richard Kim, Alexis D. Leal, Aparna Parikh, David P. Ryan, Shining Wang, Brittany Bahamon, Neeraj Gupta, Aaron Moss, Joanna Pye, Harry Miao, Haig Inguilizian, James M. Cleary
Publikováno v:
Cancer Chemotherapy and Pharmacology. 91:301-301
Autor:
Daniel J. DeAngelo, Andrew L. Kung, Ilene Galinsky, Cynthia K. Hahn, Jon C. Aster, William C. Hahn, Giovanni Roti, Anna C. Schinzel, Stacey M. Frumm, Richard Stone, Haig Inguilizian, Versha Banerji, Loretta S. Li, Gabriela Alexe, Kwan T. Chow, Linda Ross, Kenneth N. Ross, Rose M. Kakoza, Nicola Tolliday, Kimberly Stegmaier
Publikováno v:
Journal of Clinical Investigation. 122:935-947
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults. Long-term survival of patients with AML has changed little over the past decade, necessitating the identification and validation of new AML targets. Integration of geno
Autor:
Andrew L. Kung, Mamatha M. Reddy, Anagha Deshpande, Ross L. Levine, Margret S. Fernandes, James D. Griffin, Omar Abdel-Wahab, Ellen Weisberg, Haig Inguilizian, Martin Sattler
Publikováno v:
Leukemia
Myeloproliferative neoplasms (MPNs) are characterized by overproduction of myeloid lineage cells with frequent acquisition of oncogenic JAK2V617F kinase mutations. The molecular mechanisms that regulate energy requirements in these diseases are poorl
Autor:
Handrean Soran, Simon Jones, Kerry Culm-Merdek, Ana Cristina Puga, Natalie Lippa, Melissa P. Wasserstein, Beth L. Thurberg, Gerald F. Cox, Haig Inguilizian, Eli Shamiyeh, George A. Diaz
Publikováno v:
Molecular genetics and metabolism. 116(1-2)
Background Olipudase alfa, a recombinant human acid sphingomyelinase (rhASM), is an investigational enzyme replacement therapy (ERT) for patients with ASM deficiency [ASMD; Niemann–Pick Disease (NPD) A and B]. This open-label phase 1b study assesse
Autor:
Melissa P. Wasserstein, Simon A. Jones, Handrean Soran, George Diaz, Natalie Lippa, Beth L. Thurberg, Kerry Culm-Merdek, Elias Shamiyeh, Haig Inguilizian, Ana Cristina Puga
Publikováno v:
Molecular Genetics and Metabolism. 114:S125-S126
Autor:
Margaret A. Shipp, Craig H. Mermel, Andrew L. Kung, Todd R. Golub, Ahmet Dogan, Treeve Currie, Gad Getz, Rameen Beroukhim, Jeffery L. Kutok, Kelly T. Yeda, Yansheng Hao, Scott J. Rodig, Thomas M. Habermann, Haig Inguilizian, Bjoern Chapuy, Stefano Monti, Donna Neuberg, Kunihiko Takeyama
Publikováno v:
Cancer cell. 22(3)
SummaryDiffuse large B cell lymphoma (DLBCL) is a clinically and biologically heterogeneous disease with a high proliferation rate. By integrating copy number data with transcriptional profiles and performing pathway analysis in primary DLBCLs, we id
Autor:
Ahmet Dogan, Andrew L. Kung, Gad Getz, Jeffery L. Kutok, Donna Neuberg, Bjoern Chapuy, Scott J. Rodig, Stefano Monti, Craig H. Mermel, Kunihiko Takeyama, Todd R. Golub, Rameen Beroukhim, Treeve Currie, Haig Inguilizian, Thomas M. Habermann, Kelly T. Yeda, Yansheng Hao, Margaret A. Shipp
Publikováno v:
Blood. 120:1534-1534
Abstract 1534 + equal contributions Diffuse large B-cell lymphoma (DLBCL) is a clinically and biologically heterogeneous disease with a high proliferation rate and infrequent somatic mutations of TP53 and genes encoding cell cycle pathway components.
Autor:
Kwan T. Chow, Richard Stone, Linda Ross, Versha Banerji, William C. Hahn, Anna C. Schinzel, Kenneth N. Ross, Rose M. Kakoza, Loretta S. Li, Haig Inguilizian, Kimberly Stegmaier, Daniel J. DeAngelo, Ilene Galinsky, Stacey M. Frumm, Andrew L. Kung, Cynthia K. Hahn
Publikováno v:
Blood. 116:1000-1000
Abstract 1000 The treatment of acute myeloid leukemia (AML) poses a vexing challenge despite an improved understanding of its molecular pathogenesis. A two-hit theory has been proposed for the pathogenesis of AML where the first hit imparts a prolife